Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | PARP1 | P09874 | 2/20 | 0.39 |
| ▸ | PARP2 | Q9UGN5 | 2/20 | 0.39 |
| ▸ | PARP3 | Q9Y6F1 | 1/20 | 0.39 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.39 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.38 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.38 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.38 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3411577 | 0.85 | MAPT (0.43) | ALDH1A1LMNAMAPTSMN1; SMN2PARP1 | |
| SCHEMBL3432748 | 0.81 | PARP1 (0.37) | NPSR1PARP1NOTUM | |
| SCHEMBL6517899 | 0.78 | NOTUM (0.49) | NPSR1ALDH1A1LMNAMAPTPDE10A | |
| SCHEMBL29333627 | 0.75 | ALDH1A1 (0.42) | NPSR1ALDH1A1LMNAMAPTSMN1; SMN2 | |
| SCHEMBL18049518 | 0.75 | ADORA3 (0.47) | NPSR1ALDH1A1SMN1; SMN2ADORA3ADORA2A | |
| SCHEMBL23928488 | 0.72 | ALDH1A1 (0.67) | ALDH1A1LMNAMAPTSMN1; SMN2 | |
| SCHEMBL4774277 | 0.72 | DGAT1 (0.44) | NPSR1 | |
| SCHEMBL3413163 | 0.70 | CA12 (0.41) | ALDH1A1LMNAMAPTPARP1 | |
| SCHEMBL2011238 | 0.69 | KDM4E (0.46) | ALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL12700430 | 0.69 | NOTUM (0.48) | NOTUM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8362030-B2 | Tricyclic derivatives as inhibitors of poly(ADP-ribose) polymerase (PARP) | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI S.R.L. (IT) | 2013-01-29 | — | — | US | disclosed |
| US-20110053911-A1 | TRICYCLIC DERIVATIVES AS INHIBITORS OF POLY(ADP-RIBOSE) POLYMERASE (PARP) | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI S.R.L. (IT) | 2011-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110053911-A1 | TRICYCLIC DERIVATIVES AS INHIBITORS OF POLY(ADP-RIBOSE) POLYMERASE (PARP) | PARP1, PARP2, PARP11 | NPSR1 4339/4885ALDH1A1 305/4885LMNA 504/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.